The Phase 3 clinical trial investigating evolocumab (Repatha) in patients with ST Elevation Myocardial Infarction (STEMI) reached its primary completion on 2025-12-31. This study, which enrolled 166 participants, aims to compare the size of myocardial infarct between evolocumab and control groups.
Background
The trial focuses on evolocumab (Repatha) for patients experiencing ST Elevation Myocardial Infarction (STEMI). STEMI is a severe type of heart attack where one of the heart's major arteries is blocked.
Trial design
The study (NCT06081803) is a Phase 3 clinical trial with an enrollment of 166 participants. It investigates evolocumab (Repatha) in patients diagnosed with ST Elevation Myocardial Infarction who are undergoing primary percutaneous coronary intervention (PCI). The trial's goal is to compare the size of myocardial infarct between the evolocumab and control groups. Participants in the evolocumab group receive 420 mg via subcutaneous injection before PCI, and all participants will undergo a cardiac MRI 4 weeks after primary reperfusion.
What this means
The primary completion of this Phase 3 trial marks a significant milestone in the study of evolocumab for patients with ST Elevation Myocardial Infarction. While no results are available yet, the completion indicates that data collection for the primary endpoint is concluded. Future analysis of this data will determine evolocumab's impact on myocardial infarct size in this patient population, potentially offering new insights for managing acute heart attack.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06081803, titled "Evolocumab in STEMI," was updated to reflect primary completion on 2025-12-31 on clinicaltrials.gov.